These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38614211)

  • 1. SIRS epidemics with individual heterogeneity of immunity waning.
    El Khalifi M; Britton T
    J Theor Biol; 2024 Jun; 587():111815. PubMed ID: 38614211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extending susceptible-infectious-recovered-susceptible epidemics to allow for gradual waning of immunity.
    El Khalifi M; Britton T
    J R Soc Interface; 2023 Sep; 20(206):20230042. PubMed ID: 37700711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mathematical assessment of the role of waning and boosting immunity against the BA.1 Omicron variant in the United States.
    Safdar S; Ngonghala CN; Gumel AB
    Math Biosci Eng; 2023 Jan; 20(1):179-212. PubMed ID: 36650762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the impact of vaccination strategies on the spread of COVID-19, including a novel household-targeted vaccination strategy.
    Voigt A; Omholt S; Almaas E
    PLoS One; 2022; 17(2):e0263155. PubMed ID: 35108311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of heterogeneous age-group contact patterns on critical vaccination rates for herd immunity to SARS-CoV-2.
    Saldaña J; Scoglio C
    Sci Rep; 2022 Feb; 12(1):2640. PubMed ID: 35173229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
    McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
    Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study.
    Zhou W; Tang B; Bai Y; Shao Y; Xiao Y; Tang S
    Vaccine; 2022 Nov; 40(49):7141-7150. PubMed ID: 36328883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of immune evasion, waning and boosting on dynamics of population mixing between a vaccinated majority and unvaccinated minority.
    Fisman DN; Amoako A; Simmons A; Tuite AR
    PLoS One; 2024; 19(4):e0297093. PubMed ID: 38574059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herd immunity under individual variation and reinfection.
    Montalbán A; Corder RM; Gomes MGM
    J Math Biol; 2022 Jun; 85(1):2. PubMed ID: 35773525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contact-adjusted Immunity Levels against SARS-CoV-2 in Korea and Prospects for Achieving Herd Immunity.
    Chun JY; Jeong H; Kim Y
    J Korean Med Sci; 2021 Oct; 36(38):e272. PubMed ID: 34609093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility to Resurgent COVID-19 Outbreaks Following Vaccine Rollouts: A Modeling Study.
    Neofotistos G; Angeli M; Mattheakis M; Kaxiras E
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical assessment of the roles of age heterogeneity and vaccination on the dynamics and control of SARS-CoV-2.
    Pant B; Gumel AB
    Infect Dis Model; 2024 Sep; 9(3):828-874. PubMed ID: 38725431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-dependent heterogeneity leads to transient suppression of the COVID-19 epidemic, not herd immunity.
    Tkachenko AV; Maslov S; Elbanna A; Wong GN; Weiner ZJ; Goldenfeld N
    Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33833080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Review of the concept of herd immunity, in the context of COVID-19 epidemic and the development of vaccines].
    Canals L M
    Rev Chilena Infectol; 2021 Aug; 38(4):495-499. PubMed ID: 34652394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network models to evaluate vaccine strategies towards herd immunity in COVID-19.
    Tetteh JNA; Nguyen VK; Hernandez-Vargas EA
    J Theor Biol; 2021 Dec; 531():110894. PubMed ID: 34508758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can COVID-19 herd immunity be achieved at a city level?
    Arbel Y; Arbel Y; Kerner A; Kerner M
    PLoS One; 2024; 19(5):e0299574. PubMed ID: 38809902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects.
    Bicher M; Rippinger C; Schneckenreither G; Weibrecht N; Urach C; Zechmeister M; Brunmeir D; Huf W; Popper N
    Sci Rep; 2022 Feb; 12(1):2872. PubMed ID: 35190590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines and herd immunity: Perspectives, challenges and prospects.
    Wong RSY
    Malays J Pathol; 2021 Aug; 43(2):203-217. PubMed ID: 34448786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China.
    Liu H; Zhang J; Cai J; Deng X; Peng C; Chen X; Yang J; Wu Q; Chen X; Chen Z; Zheng W; Viboud C; Zhang W; Ajelli M; Yu H
    BMC Med; 2022 Jan; 20(1):37. PubMed ID: 35094714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trajectory of individual immunity and vaccination required for SARS-CoV-2 community immunity: a conceptual investigation.
    Saad-Roy CM; Levin SA; Metcalf CJE; Grenfell BT
    J R Soc Interface; 2021 Feb; 18(175):20200683. PubMed ID: 33530857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.